To view enhanced digital features for this article go to https://doi.org/10.6084/m9.figshare.11353028.
Buprenorphine is a Schedule III opioid analgesic with unique pharmacodynamic and pharmacokinetic properties that may be preferable to those of Schedule II full μ-opioid receptor agonists. The structure of buprenorphine allows for multimechanistic interactions with opioid receptors μ, δ, κ, and opioid receptor-like 1. Buprenorphine is considered a partial agonist with very high binding affinity for the μ-opioid receptor, an antagonist with high binding affinity for the δ- and κ-opioid receptors, and an agonist with low binding affinity for the opioid receptor-like 1 receptor. Partial agonism at the μ-opioid receptor does not provide partial analgesia, but rather analgesia equivalent to that of full μ-opioid receptor agonists. In addition, unlike full μ-opioid receptor agonists, buprenorphine may have a unique role in mediating analgesic signaling at spinal opioid receptors while having less of an effect on brain receptors, potentially limiting classic opioid-related adverse events such as euphoria, addiction, or respiratory depression. The pharmacokinetic properties of buprenorphine are also advantageous in a clinical setting, where metabolic and excretory pathways allow for use in patients requiring concomitant medications, the elderly, and those with renal or hepatic impairment. The unique pharmacodynamic and pharmacokinetic properties of buprenorphine translate to an effective analgesic with a potentially favorable safety profile compared with that of full μ-opioid receptor agonists for the treatment of chronic pain.
A plain language summary is available for this article.
US Health and Human Services. HHS acting secretary declares public health emergency to address national opioid crisis. Available at: https://www.hhs.gov/about/news/2017/10/26/hhs-acting-secretary-declares-public-health-emergency-address-national-opioid-crisis.html. Accessed Jan 24, 2019.
National Institute on Drug Abuse. Opioid overdose crisis. Updated January 2019. Available at: https://www.drugabuse.gov/drugs-abuse/opioids/opioid-overdose-crisis. Accessed March 20, 2019.
Substance Abuse and Mental Health Services Administration. Key substance use and mental health indicators in the United States: results from the 2017 national survey on drug use and health (HHS Publication No. SMA 18-5068, NSDUH Series H-53). 2018. Available at: https://www.samhsa.gov/data/report/2017-nsduh-annual-national-report. Accessed March 20, 2019.
US Department of Health and Human Services. Pain management best practices inter-agency task force report: updates, gaps, inconsistencies, and recommendations. 2019. Available at: https://www.hhs.gov/sites/default/files/pmtf-final-report-2019-05-23.pdf. Accessed July 1, 2019.
The National Alliance of Advocates for Buprenorphine Treatment. Buprenorphine: a treatment for opioid addiction in the privacy of a doctor’s office. 2015. Available at: http://www.naabt.org/documents/naabt_brochure%20Version%202.pdf. Accessed March 25, 2019.
Pergolizzi J, Boger RH, Budd K, Dahan A, Erdine S, Hans G, et al. Opioids and the management of chronic severe pain in the elderly: consensus statement of an international expert panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pain Pract. 2008;8(4):287–313. PubMedCrossRefPubMedCentral
Schiller EY, Mechanic OJ. Opioid Overdose. StatPearls. Treasure Island (FL) 2019.
Foster B, Twycross R, Mihalyo M, Wilcock A. Buprenorphine. J Pain Symptom Manag. 2013;45(5):939–49. CrossRef
Buprenorphine thresholds (euphoria, respiratory depression, and analgesia) and activities location (brain v spinal). Available at: https://paindr.com/wp-content/uploads/2019/08/Figure-3.tif. Accessed Oct 16, 2019.
US Department of Health and Human Services: Substance Abuse and Mental Health Service Administration. Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction. DHHS Publication No. (SMA) 04-3939. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2004.
The National Alliance of Advocates for Buprenorphine Treatment. Thorough technical explanation of buprenorphine. Available at: https://www.naabt.org/education/technical_explanation_buprenorphine.cfm. Accessed April 8, 2019.
Benedict PE, Benedict MB, Su TP, Bolling SF. Opiate drugs and delta-receptor-mediated myocardial protection. Circulation. 1999;100(19 Suppl):II357–60. PubMed
Drug Enforcement Administration Diversion Control Division. Rescheduling of buprenorphine from Schedule V to Schedule III. 2002. Available at: https://www.deadiversion.usdoj.gov/fed_regs/rules/2002/fr1007.htm. Accessed March 20, 2019.
Opioid receptor delineation and activities. Available at: https://paindr.com/wp-content/uploads/2019/08/Figure-4.tif. Accessed Oct 16, 2019.
Gimbel J, Spierings EL, Katz N, Xiang Q, Tzanis E, Finn A. Efficacy and tolerability of buccal buprenorphine in opioid-experienced patients with moderate to severe chronic low back pain: results of a phase 3, enriched enrollment, randomized withdrawal study. Pain. 2016;157(11):2517–26. PubMedPubMedCentralCrossRef
Poulain P, Denier W, Douma J, Hoerauf K, Samija M, Sopata M, et al. Efficacy and safety of transdermal buprenorphine: a randomized, placebo-controlled trial in 289 patients with severe cancer pain. J Pain Symptom Manag. 2008;36(2):117–25. CrossRef
Belbuca ® (buprenorphine buccal film) [prescribing information]. Raleigh, NC: BioDelivery Sciences International, Inc.; 2018.
Butrans ® (buprenorphine transdermal system) [prescribing information]. Stamford, CT: Purdue Pharma L.P.; 2018.
Marquet P. Pharmacology of high dose buprenorphine. In: Kintz P, Marquet P, editors. Buprenorphine Therapy of Opiate Addiction. Totowa (NJ): Humana Press; 2002. p. 1–11.
Probuphine [prescribing information]. South San Francisco, CA. Titran Pharmaceuticals, Inc; 2018.
Moody DE, Slawson MH, Strain EC, Laycock JD, Spanbauer AC, Foltz RL. A liquid chromatographic-electrospray ionization-tandem mass spectrometric method for determination of buprenorphine, its metabolite, norbuprenorphine, and a coformulant, naloxone, that is suitable for in vivo and in vitro metabolism studies. Anal Biochem. 2002;306(1):31–9. PubMedCrossRefPubMedCentral
Cone EJ, Gorodetzky CW, Yousefnejad D, Buchwald WF, Johnson RE. The metabolism and excretion of buprenorphine in humans. Drug Metab Dispos. 1984;12(5):577–81. PubMed
Gordon A, Callaghan D, Spink D, Cloutier C, Dzongowski P, O’Mahony W, et al. Buprenorphine transdermal system in adults with chronic low back pain: a randomized, double-blind, placebo-controlled crossover study, followed by an open-label extension phase. Clin Ther. 2010;32(5):844–60. PubMedCrossRefPubMedCentral
- A Narrative Pharmacological Review of Buprenorphine: A Unique Opioid for the Treatment of Chronic Pain
- Springer Healthcare
Pain and Therapy
Print ISSN: 2193-8237
Elektronische ISSN: 2193-651X
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II